Epidemiology and clinical features of human anaplasmosis in Alsace
Official title: Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace: a Retrospective and Multicenter Study
Run by University Hospital, Strasbourg, France · NCT07312474 · Data updated 2026-11-12
This project will see how Anaplasma phagocytophilum infections present and progress in adults in Alsace using PCR-confirmed cases.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | October 2, 2024 |
| Main results expected | February 2026 |
| Study ends | February 2026 |
| Registry record updated | December 31, 2025 |
| Trial ID | NCT07312474 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with a PCR-confirmed Anaplasma phagocytophilum infection who agree to participate are ideal candidates.
✕Probably not a fit
People without PCR confirmation, children under 18, or anyone who refuses consent are not eligible and will not benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational project enrolling adults (≥18) with PCR-confirmed Anaplasma infection seen at the Infectious Diseases department of CHU de Strasbourg. Investigators will collect epidemiological data, clinical signs and symptoms, laboratory and biological findings, treatment given, and clinical outcomes. The goal is to characterize typical presentations, frequency of severe complications (for example cytopenias, respiratory distress, macrophage activation), and outcomes in the local Alsace population. Results will be compared with published series from other countries to refine regional recognition and management.
Why it matters
Potential benefit: If successful, the project could help clinicians recognize anaplasmosis earlier in this region, leading to faster treatment and fewer severe complications.
How similar studies have gone: Similar observational case series from the U.S. and several European countries have described clinical patterns and supported doxycycline treatment, so the approach is well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult subjct (≥18 years) * Presenting with a PCR-confirmed infection of Anaplasma Exclusion Criteria: \- Refusal to participate in the study
Where it's running
-
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Victor GERBER, MD
- Email: victor.gerber@chru-strasbourg.fr
- Phone: 33 3.88.11.67.68
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tick-borne infections in Finland: a broad, multicenter look at Lyme, TBE and other infections
This study tests how common and how these infections show up in people with suspected tick-borne disease in Finland.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.